BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a leader in AI-driven drug discovery, has announced advancements in its ongoing collaboration with the Lieber Institute for Brain Development (LIBD). This collaboration has yielded pivotal insights into the molecular pathwa...
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a leader in AI-driven drug discovery, has announced advancements in its ongoing collaboration with the Lieber Institute for Brain Development (LIBD). This collaboration has yielded pivotal insights into the molecular pathwa...
Sharps Technology: A Comprehensive Look at the New Five-Year Sales Agreement and Its Implications.
Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") has recently announced a accomplishment in its business operations through the successful negotiation and signing of a five-year sales agreement with a leading U.S.-based supplier of medical saline and water products. $Sharps Technology(STSS.US$
https://stockregion.app/p/technology-company-announces-five
Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") has recently announced a accomplishment in its business operations through the successful negotiation and signing of a five-year sales agreement with a leading U.S.-based supplier of medical saline and water products. $Sharps Technology(STSS.US$
https://stockregion.app/p/technology-company-announces-five
Predictive Oncology's Foray into Biomarker Discovery.
Predictive Oncology Inc. (NASDAQ: POAI), recognized for its advancements in AI-driven drug discovery and biologics, has recently announced its strategic entry into the biomarker discovery market. This expansion leverages the company's AI/ML-driven platform, which has shown promise in predicting patient outcomes and drug responses in oncology. The move follows compe...
Predictive Oncology Inc. (NASDAQ: POAI), recognized for its advancements in AI-driven drug discovery and biologics, has recently announced its strategic entry into the biomarker discovery market. This expansion leverages the company's AI/ML-driven platform, which has shown promise in predicting patient outcomes and drug responses in oncology. The move follows compe...
Windtree Therapeutics: Advancing Istaroxime Clinical Development.
Windtree Therapeutics, Inc. (“Windtree” or the “Company”), listed on the Nasdaq Capital Market under the ticker symbol WINT, has recently provided an update on the clinical and business development of istaroxime. This innovative biotechnology company focuses on developing therapies for critical conditions and diseases, emphasizing early and late-stage tre...
Windtree Therapeutics, Inc. (“Windtree” or the “Company”), listed on the Nasdaq Capital Market under the ticker symbol WINT, has recently provided an update on the clinical and business development of istaroxime. This innovative biotechnology company focuses on developing therapies for critical conditions and diseases, emphasizing early and late-stage tre...
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Tonmya™ (cyclobenzaprine HCl sublingual tablets) for th...
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Tonmya™ (cyclobenzaprine HCl sublingual tablets) for th...
1
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma.
Checkpoint Therapeutics, Inc. (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for cosibelimab. This investigational anti-PD-L1 a...
Checkpoint Therapeutics, Inc. (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for cosibelimab. This investigational anti-PD-L1 a...
Pharmaceuticals Company Releases Positive Preclinical Study Data For Neurological Disorder Treatment
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a pre-clinical-stage pharmaceutical company, has recently announced new insights from additional preclinical study data regarding the mechanism of action and toxicology of its novel oral ketamine analog, Ketamir-2. This latest development marks prog...
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a pre-clinical-stage pharmaceutical company, has recently announced new insights from additional preclinical study data regarding the mechanism of action and toxicology of its novel oral ketamine analog, Ketamir-2. This latest development marks prog...
1
Chemomab Therapeutics Announces Positive Phase 2 Trial Results for CM-101 in Primary Sclerosing Cholangitis.
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or "the Company"), a clinical-stage biotechnology company focused on developing innovative treatments for fibro-inflammatory diseases with high unmet needs, recently announced substantial progress in its Phase 2 clinical trial for CM-101. The t...
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or "the Company"), a clinical-stage biotechnology company focused on developing innovative treatments for fibro-inflammatory diseases with high unmet needs, recently announced substantial progress in its Phase 2 clinical trial for CM-101. The t...
Sol-Gel Technologies Announces Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company dedicated to pioneering treatments for severe skin conditions, has announced the signing of six exclusive license agreements. These agreements aim to commercialize two of its leading products, TWYNEO® and EPSOLAY®, across Europe and South Afri...
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company dedicated to pioneering treatments for severe skin conditions, has announced the signing of six exclusive license agreements. These agreements aim to commercialize two of its leading products, TWYNEO® and EPSOLAY®, across Europe and South Afri...
1
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial.
Psyence Biomedical Ltd. (Nasdaq: PBM), referred to as "Psyence Biomed" or "the Company", recently announced advancements in their ongoing efforts to explore nature-derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in a Palliative Care ...
Psyence Biomedical Ltd. (Nasdaq: PBM), referred to as "Psyence Biomed" or "the Company", recently announced advancements in their ongoing efforts to explore nature-derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in a Palliative Care ...